Mifomelatide (TCMCB07)
Cancer Cachexia
Phase 2Active
Key Facts
About Endevica Bio
Endevica Bio is a clinical-stage biotech leveraging its expertise in peptide and peptidomimetic chemistry to drug the melanocortin (MC) system, the body's central regulator of metabolic homeostasis. In March 2026, the company spun out its lead metabolic assets into a new entity, Kalohexis, which is advancing a pipeline including an oral dual MC3R/MC4R agonist for obesity (710GO, Phase 1-ready) and a dual antagonist for cancer cachexia (mifomelatide, Phase 2). Endevica's core strategy is to develop potent, selective, and bioavailable therapeutics that offer safer and more durable efficacy compared to existing modalities, particularly in high-need metabolic indications.
View full company profileTherapeutic Areas
Other Cancer Cachexia Drugs
| Drug | Company | Phase |
|---|---|---|
| NGM120 | NGM Biopharmaceuticals | Phase 2 |
| Rilogrotug (AV-380) | AVEO Oncology | Phase 1/2 |
| Espindolol (MT-102) | Numedicus | Phase 2/Spin-out |
| S-pindolol benzoate (ACM-001.1) | Actimed Therapeutics | Phase 2 |